Galderma announced that the Swedish Medical Products Agency (Lakemedelsverket) issued key manufacturing license updates that will allow the company to pursue its ambitious growth and innovation roadmap. The license updates, issued following the agency's good manufacturing practices (GMP) inspection of Galderma's center of excellence in Uppsala, Sweden, enable Galderma to manufacture and perform bioanalytical testing on Relabotulinum toxinA (QM1114). One of Galderma's key innovation pipeline assets in Injectable Aesthetics, Relabotulinum toxinA is a next-generation liquid neuromodulator in Injectable Aesthetic developed using Galderma's proprietary PEARL?

technology. This technology preserves the molecule's integrity, resulting in a highly active, complex-free botulinum toxin A. Galderma's center of Excellence in Uppsala is one of the company's four manufacturing and R&D facilities around the world. Galderma is currently expanding this site in response to growing global demand for science-based premium dermatology solutions.

The new facility--scheduled for completion by the end of 2025-- will be strategically positioned to cater to the higher demand for injectable aesthetics treatments worldwide and the development of upcoming products. With a modular design that allows for seamless further expansion in the future, this forward-looking approach aligns with both Galderma's growth strategy and its environment, social and governance (ESG) roadmap. Developed by Galderma, Relabotulinum toxinA is a highly active, innovative, complex-free and ready-to-use liquid botulinum toxin A with a proprietary strain.

Manufactured using a unique state-of-the-art process, it is designed as a liquid. This avoids the need to reconstitute from powder and thus eliminates the variability, errors and risks associated with reconstitution, which would be expected to improve the consistency of results. Relabotulinum toxinA is currently being investigated globally, with a view to expanding its neuromodulator portfolio ?

part of the broadest injectable aesthetics portfolio on the market.